TriSalus Life Sciences, Inc. (TLSI)
- Previous Close
9.93 - Open
9.75 - Bid --
- Ask 9.42 x 200
- Day's Range
9.30 - 9.82 - 52 Week Range
3.32 - 12.83 - Volume
205,790 - Avg. Volume
38,752 - Market Cap (intraday)
281.419M - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-6.73 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
16.00
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
trisaluslifesci.comRecent News: TLSI
Performance Overview: TLSI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLSI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLSI
Valuation Measures
Market Cap
281.42M
Enterprise Value
271.24M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.75
Price/Book (mrq)
--
Enterprise Value/Revenue
14.65
Enterprise Value/EBITDA
-4.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-141.84%
Return on Equity (ttm)
--
Revenue (ttm)
18.51M
Net Income Avi to Common (ttm)
-63.28M
Diluted EPS (ttm)
-6.73
Balance Sheet and Cash Flow
Total Cash (mrq)
11.78M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-51.81M